In addition to the successful workshop in Côte d'Ivoire in February, members of the Pediatric Praziquantel Consortium Access Team met once again in March for a two-day workshop in Nairobi, Kenya.

Towards the end of February, members of the Pediatric Praziquantel Consortium Access Team met in Côte d’Ivoire for a two-day workshop held on the campus of the University Félix Houphouët-Boigny (UFHB) in Abidjan.

January 30, 2022, marks the third annual World NTD Day – a global event that draws attention to neglected tropical diseases (NTDs) worldwide, with the aim of translating awareness into action.

On Wednesday 8 December, by way of a public webinar, the Pediatric Praziquantel Consortium celebrated a major milestone: the completion of the pivotal Phase III trial of arpraziquantel – a potential new treatment option for the estimated 50 million preschool-age children suffering from schistosomiasis.

Join us on Wednesday 8 December as we celebrate a major milestone for the Consortium: the completion of the pivotal Phase III trial of arpraziquantel – a potential new treatment option for the estimated 50 million preschool-aged children suffering from schistosomiasis.

The Pediatric Praziquantel Consortium is pleased to announce the completion of its pivotal Phase III trial of arpraziquantel – a potential new treatment option for the estimated 50 million preschool-aged children suffering from schistosomiasis.

Following two successful workshops in Kenya and Uganda in August, members of the Pediatric Praziquantel Consortium Access Team gathered together onc

In a short video interview, Dr. Benjamin Dälken, Senior Director, Global Program Lead Immunology & Global Health at Merck, and Global Program Lead of the Pediatric Praziquantel Consortium, reflects on the progress made over the last year for the Consortium.

Earlier this year, the Consortium celebrated the official launch of its ADOPT1 Program – an implementation research program that paves the way for the large-scale delivery of the new pediatric medication to treat schistosomiasis in preschool-age children in endemic countries, once registered.

In August, two workshops were held in Kenya and Uganda, bringing together members of the Pediatric Praziquantel Consortium’s Access Team in person for the first time since the launch of t

To reinforce the efforts of the Pediatric Praziquantel Consortium to make a child-friendly treatment available to preschool-age children suffering from schistosomiasis, we are pleased to join forces with the following organizations

Today, 15 July 2021, it was announced that Pediatric Praziquantel Consortium partner, Merck, has entered into a contract manufacturing agreement with Universal Corporation Ltd. in Kenya.

Today – International Day of the African Child – we celebrate the rights of children to a good quality of life and a healthy, prosperous future.

In April, the Pediatric Praziquantel Consortium celebrated the official launch of its ADOPT program – an implementation research program that paves the way for the large-scale delivery of a child-friendly formulation to treat schistosomiasis in preschool-age children in endemic countries.

Today, 7 April, is World Health Day. Celebrated annually to mark the founding of the World Health Organization (WHO), World Health Day draws attention to a specific health challenge of global concern.